Blog
RSS FeedPosted by Michael Wonder on 26 Sep 2022
Pfizer and BioNTech submit application to U.S. FDA for Emergency Use Authorisation of Omicron BA.4/BA.5 adapted bivalent vaccine booster in children 5 through 11 years of age
26 September 2022 - Pfizer and BioNTech today announced they have completed a submission to the US FDA requesting Emergency Use ...
Posted by Michael Wonder on 24 Sep 2022
Moderna asks FDA to authorise omicron Covid boosters for children as young as 6 years old
23 September 2022 - The Centers for Disease Control and Prevention, in a document published Tuesday, said it expects children to ...
Posted by Michael Wonder on 19 Sep 2022
Pharmacists can now prescribe Paxlovid, but barriers persist
19 September 2022 - Recently, the FDA expanded access to COVID-19 treatment by authorising state-licensed pharmacists to prescribe Paxlovid to eligible ...
Posted by Michael Wonder on 07 Sep 2022
Statement by President Biden on FDA and CDC authorising updated COVID-19 vaccines
6 September 2022 - This week, we begin a new phase in our COVID-19 response. We are launching a new ...
Posted by Michael Wonder on 31 Aug 2022
FDA authorises Moderna, Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose
31 August 2022 - Today, the US FDA amended the emergency use authorisations of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech ...
Posted by Michael Wonder on 29 Aug 2022
FDA expected to authorise Moderna, Pfizer-BioNTech Omicron boosters
29 August 2022 - The move would set the stage for the Biden administration to begin offering the reformulated vaccine shortly ...
Posted by Michael Wonder on 25 Aug 2022
FDA plans to authorise bivalent boosters by Labor Day, sources say
24 August 2022 - The FDA plans to authorise updated versions of Pfizer-BioNTech’s and Moderna’s Covid boosters around Labor Day, ...
Posted by Michael Wonder on 23 Aug 2022
Moderna completes application to US FDA for emergency use authorisation of omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222
23 August 2022 - Clinical data available for Moderna's bivalent COVID-19 booster vaccines have met all primary endpoints and support ...
Posted by Michael Wonder on 22 Aug 2022
Pfizer and BioNTech submit application to U.S. FDA for emergency use authorisation of Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine
22 August 2022 - Companies have rapidly scaled production and stand ready to deliver doses of Omicron BA.4/BA.5 adapted bivalent vaccines ...
Posted by Michael Wonder on 15 Aug 2022
Novavax submits application to the U.S. FDA for emergency use authorisation for Novavax COVID-19 vaccine, adjuvanted as a booster in adults aged 18 and older
15 August 2022 - If authorised, Novavax' vaccine would be the first protein-based COVID-19 booster for adults. ...
Posted by Michael Wonder on 26 Jul 2022
Despite their anger over high drug prices, Americans are giving pharma credit for helping contain COVID-19
26 July 2022 - Nearly three quarters of Americans give the pharmaceutical industry credit for helping contain COVID-19 — and for ...
Posted by Michael Wonder on 20 Jul 2022
Statement by President Joe Biden on FDA and CDC authorising Novavax’s COVID-19 vaccine for adults
19 July 2022 - Today is another step forward in our nation’s fight against the virus. Following an independent scientific review ...
Posted by Michael Wonder on 13 Jul 2022
FDA authorises emergency use of Novavax COVID-19 vaccine, adjuvanted
13 July 2022 - Today, the U.S. FDA issued an emergency use authorisation for the Novavax COVID-19 vaccine, adjuvanted for the ...
Posted by Michael Wonder on 13 Jul 2022
Accelerating pooled licensing of medicines to enhance global production and equitable access
8 July 2022 - From October to November, 2021, the pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral ...
Posted by Michael Wonder on 09 Jul 2022
Pfizer and BioNTech announce U.S. FDA approval of their COVID-19 vaccine Comirnaty for adolescents 12 through 15 years of age
8 July 2022 - Approval of the two dose primary series is based on the totality of data through six months ...